43
CpG anti-PD-L1 Immunoconjugate for Cancer Therapy
University of Southern California
Antibody
Oncology
Hit To Lead or Lead Optimization
The antibodies are conjugated to CpG, a Toll-like receptor 9 agonist, which activates innate immune cells. Preclinical studies showed that CpG-conjugated antibodies delay tumor growth and improve survival. Chemical conjugation of CpG to checkpoint inhibitors may sensitize cold tumors to ICI treatment.